Advanced

Effect of mergers and acquisitions on drug discovery : perspective from a case study of a Japanese pharmaceutical company

Shibayama, Sotaro LU ; Tanikawa, Kunihiro; Fujimoto, Ryuhei and Kimura, Hiromichi (2008) In Drug Discovery Today 13(1-2). p.86-93
Abstract

The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level... (More)

The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level integration after M&As would reinforce fundamental research capabilities in the long term.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
in
Drug Discovery Today
volume
13
issue
1-2
pages
8 pages
publisher
Elsevier
external identifiers
  • scopus:37649033180
ISSN
1359-6446
DOI
10.1016/j.drudis.2007.10.015
language
English
LU publication?
no
id
be989541-8502-40b4-acda-5397cf13c10c
date added to LUP
2017-04-13 17:47:50
date last changed
2017-05-05 13:34:22
@article{be989541-8502-40b4-acda-5397cf13c10c,
  abstract     = {<p>The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&amp;As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level integration after M&amp;As would reinforce fundamental research capabilities in the long term.</p>},
  author       = {Shibayama, Sotaro and Tanikawa, Kunihiro and Fujimoto, Ryuhei and Kimura, Hiromichi},
  issn         = {1359-6446},
  language     = {eng},
  number       = {1-2},
  pages        = {86--93},
  publisher    = {Elsevier},
  series       = {Drug Discovery Today},
  title        = {Effect of mergers and acquisitions on drug discovery : perspective from a case study of a Japanese pharmaceutical company},
  url          = {http://dx.doi.org/10.1016/j.drudis.2007.10.015},
  volume       = {13},
  year         = {2008},
}